TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03404830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT group, MICT group
Description: The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT group, MICT group
Description: The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching.
Study: NCT01793311

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: decaffeinated coffee
Description: contains caffeine 0.5-2 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular dose coffee
Description: contains 91.8 mg of caffeine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high dose coffee
Description: contains 144 mg of caffeine
Study: NCT03413657

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Increase in intrathoracic pressure
Description: Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Increase in intrathoracic pressure
Description: Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
Study: NCT02090959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered per the dose and schedule specified in the arm.
Study: NCT03507660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study: NCT04617210

Intervention type: OTHER
Intervention: Neurocognitive tests and blood taking
Description: Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
Study: NCT00914264

Intervention type: DEVICE
Intervention: continuous positive airway pressure
Description: CPAP with adequate pressure for 1 day, 3 \& 12 months
Study: NCT04220697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG)
Description: recording of resting state EEG using 64 surface electrodes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high frequency electrical stimulation of the forearm skin (HFS)
Description: HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cutaneous mechanical pinprick stimulation
Description: Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
Study: NCT02207881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDO gel
Description: VDO gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo gel
Study: NCT01610141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Description: Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype guided warfarin dosing
Description: A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
Study: NCT00762970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Investigational soft contact lens with asperic optical design to control myopia progression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Investigational soft contact lens with asperic optical design to control myopia progression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Spectacle Lenses.
Study: NCT03133325

Intervention type: DEVICE
Group type: OTHER
Intervention: GP0045
Description: Hyaluronic acid gel

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic acid gel
Study: NCT00624923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Study: NCT00549809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV) and synchronous IMV
Description: Patients divided to receive two different modes of mechanical ventilation.
Study: NCT00666679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: mometasone
Description: mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: montelukast
Description: montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo (Placebo once-daily, for approximately 2 weeks)
Study: NCT04261491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing
Description: scaling and root planing
Study: NCT04020705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citicoline eye drops (OMK1)
Description: (OMK1) will be prescribed in the dosage of 1 drop 3 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: hypromellose based ocular lubricant
Description: will be prescribed in the dosage of 1 drop 3 times a day
Study: NCT03271021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Description: FMX101, 4% minocycline foam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam
Study: NCT02162589

Intervention type: PROCEDURE
Intervention: POEM
Description: Per oral endoscopic myotomy
Study: NCT01548378

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
Study: NCT03549533

Intervention type: OTHER
Intervention: samples of sperm
Description: As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
Study: NCT02354508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
Study: NCT04125732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGFXC1
Description: AdVEGFXC1 at one of 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGFXC1
Description: AdVEGFXC1 at one of 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGFXC1
Description: AdVEGFXC1 at one of 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGFXC1
Description: AdVEGFXC1 at one of 4 doses
Study: NCT02743377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain PET Imaging with 11C Rolipram
Description: Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain PET Imaging with 11C Rolipram
Description: Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body PET Baseline with 11C Rolipram
Description: Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body PET Baseline with 11C Rolipram
Description: Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body PET Blocked with Roflumilast
Description: Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
Study: NCT04641494

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid
Description: CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High oleic acid safflower oil capsules
Study: NCT03183700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self sampling device
Description: The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self sampling device
Description: The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer

Intervention type: OTHER
Group type: OTHER
Intervention: Cervical ThinPrep sampling
Description: Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
Study: NCT01444573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantable continuous monitor
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantable continuous monitor
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Study: NCT04500431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeting CD269 chimeric antigen receptor engineered T cells
Description: Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
Study: NCT02942238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CME
Description: the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D3
Description: the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation
Study: NCT01059123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 50 mg/kg/24H ; Per Os ; 3 times/day 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
Study: NCT01955889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Technology

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching & Strengthening Exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching & Strengthening Exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking with Pedometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking with Pedometer
Study: NCT02878681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2 mg intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2 mg intravitreal injections
Study: NCT00582686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF of Calcaneus with bone grafting
Description: The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
Study: NCT02285465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3700
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00986674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study: NCT01927029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02564874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discretionary calorie source
Description: We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discretionary calorie source
Description: We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
Study: NCT04684602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.
Study: NCT01951963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT03523988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen gel capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen gel capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen gel capsule
Study: NCT01958164

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Actilyse
Description: Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline solution
Description: Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actilyse
Description: Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actilyse
Description: Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
Study: NCT02546388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111 Pentreotide
Study: NCT04684602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.
Study: NCT01468831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg of minocycline in a pink opaque capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill with inactive ingredients in a pink opaque capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study: NCT02768870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Artificial ePTFE Chords
Description: It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
Study: NCT04388397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous Grafts
Description: Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Grafts
Description: Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
Study: NCT04459247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Oral liquid formulation of 60000 IU
Study: NCT02963610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.